Notably, 2–3% of DLBCL cases with rearrangements of MYC and either the BCL2 or BCL6 gene, so-called double-hit lymphoma (DHL), are associated with the germinal center B-cell (GCB) phenotype, frequent extranodal and central nervous system involvement, higher International Prognostic Index scores, poor response to R-CHOP therapy, and overall dismal outcome [2–6]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.